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ABSTRACT
BACKGROUND: It is believed that preemptive IV lornoxicam treatment can re-
duce the consumption of other analgesics, improve analgesic efficacy, and ameliorate
immune function during patient-controlled IV analgesia. However, the effects of
preemptive IV lornoxicam treatment on the analgesic efficacy of patient-controlled
epidural analgesia (PCEA) with morphine and on chemokine expression remain
unknown.
OBJECTIVE: The aim of this prospective, randomized, controlled study was to
observe the effects of preemptive IV lornoxicam treatment on the analgesic efficacy of
PCEA with morphine and on the expression of monocyte chemotactic protein-1 (MCP-1)
and stromal cell-derived factor-1a (SDF-1a) in women undergoing hysterectomy.
METHODS: Patients undergoing elective hysterectomy with combined spinal and
epidural anesthesia were randomized to 1 of 3 groups to receive IV lornoxicam 8 mg
before anesthesia (group 1), lornoxicam 16-mg injection before anesthesia (group 2),
or isotonic saline (control) before anesthesia. PCEA was used to treat postoperative
pain, and a visual analog scale (VAS) and the Bruggemann Comfort Scale (BCS) were
used to evaluate analgesic efficacy. Morphine consumption was recorded. To measure
plasma concentrations of MCP-1 and SDF-1a via enzyme-linked immunosorbent as-
say, venous blood samples were obtained from patients at 4 separate times: before
anesthesia (baseline); 0 (immediately after anesthesia administration); and 24 and
48 hours after surgery.
RESULTS: Forty-five patients (mean [SD} age, 41 [5} years; mean [SD} weight,
54 [6} kg) undergoing elective hysterectomy were included in the study. There were
no significant differences in VAS scores, BCS scores, or morphine consumption be-
tween the 3 groups. Compared with baseline values, MCP-1 and SDF-1a concentra-
tions were increased significantly immediately after surgery in all 3 groups (all, P <
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0.0l) and returned to near-baseline values at 24 hours postsurgery in groups 1 and 2,
and by 48 hours postsurgery in the control group. MCP-1 and SDF-1a concentrations
in groups 1 and 2 were significantly lower than those in the control group immedi-
ately (all, P < 0.0l) and 24 hours postsurgery (all, P < 0.05).
CONCLUSION: Preemptive IV lornoxicam treatment was associated with attenu-
ation of the plasma concentrations of MCP-1 and SDF-1a immediately after and
24 hours after hysterectomy and was associated with more rapid resolution to near-
baseline concentrations of both cytokines in these patients compared with controls;
however, it was not associated with significantly reducing epidural morphine con-
sumption. (Curr Ther Res Clin Exp. 2009;70:1-9) © 2009 Excerpta Medica Inc.
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INTRODUCTION
Studies have found that injury and stress caused by surgery or acute pain are the pri-
mary reasons for immune suppression during the postoperative period. 1,2 Anesthesia
and analgesia have been found to reduce surgery-induced injury and stress, thus alle-
viating immune suppression. 2,3 Conversely, some analgesics are associated with in-
creased immune suppression. 3,4 Morphine, a traditional analgesic, has been reported
to provide good analgesic efficacy but has been associated with adverse effects, includ-
ing immune suppression.3- 5 Therefore, multimodal analgesia is suggested because of
its good analgesic efficacy and fewer adverse effects. 5,6
Lornoxicam is indicated for pain management.5- S As an adjunct in postoperative
multimodal analgesia, lornoxicam has been reported to reduce analgesic consumption
and improve analgesic efficacy and immune function after surgery.5-7 However, the
effects of preemptive IV lornoxicam on the analgesic efficacy of patient-controlled
epidural analgesia (PCEA) with morphine and on chemokine expression remain un-
known. Monocyte chemotactic protein-1 (MCP-l) is a 13-chemokine and an inducible
chemokine that mainly attracts and activates monocytes and macrophages. 9,lO Stromal
cell-derived factor-1a (SDF-1a) is an a-chemokine and a constructive chemokine that
mainly induces lymphocytes and hematopoietic cells. 9,1l Both MCP-1 and SDF-1a
play important roles in the immune response. 9- 11
We designed a prospective, randomized, controlled study to observe the effects of
preemptive IV lornoxicam treatment on the analgesic efficacy of PCEA with mor-
phine and on the expression of MCP-1 and SDF-1a in women undergoing hysterec-
tomy with combined spinal and epidural anesthesia (CSEA). We hypothesized that
preemptive IV lornoxicam treatment might improve the analgesic efficacy of PCEA,
reduce epidural morphine consumption, and decrease the plasma concentrations of
MCP-1 and SDF-1a after hysterectomy.
PATIENTS AND METHODS
The ethics committee of Affiliated Suzhou Hospital of Nanjing Medical University
(Suzhou, People's Republic of China) approved the study protocol. Written informed
consent was obtained from all patients.
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PATIENTS
Patients aged 30 to 48 years weighing 45 to 65 kg who met the criteria for the
American Society of Anesthesiologists (ASA) physical status I or II and who were
undergoing elective hysterectomy with CSEA were eligible for the study. Patients
were excluded from the study if they had impaired kidney or liver function; upper-
range anemia (hemoglobin <90 giL); history of asthma, blood coagulation disorder, or
allergy to NSAIDs; or infection within 2 weeks or peptic ulcer within 6 months prior
to entering the study. Patients were also excluded if they were receiving radiotherapy,
chemotherapy, or immunosuppressants; received a blood transfusion before or during
the hysterectomy; or were receiving any long-acting medication (eg, digoxin, furo-
semide, monoamine oxidase inhibitor, benzodiazepine, barbital) that might influence
the efficacy of lornoxicam.
The study patients were randomized into 3 groups using a random digits table
(randomization by Q.-FT.). Before the administration of anesthesia, lornoxicam 8 mg
(group 1), lornoxicam 16 mg (group 2), or isotonic saline (control) was administered
intravenously at equal volumes (4 mL). The allocation sequences were contained in a
set of sealed envelopes, and the other researchers, including the evaluators involved in
the study, were blinded to treatment assignments.
ANESTHESIA AND SURGERY
Phenobarbital sodium 0.1 g and atropine 0.5 mg were administered intramuscu-
larly 30 minutes before anesthesia was administered. After the patients were trans-
ferred to the operating room, oxygen 3 Umin was given via nasal cannula. CSEA was
performed in the same manner in each patient. After skin infiltration with 1% pro-
caine, the epidural space was identified at the L2 to L3 vertebral interspace using a
17-G Tuohy needle (Changshen Co., Changzhou, People's Republic of China) and
the loss-of-resistance-to-air technique. Using the needle-through-needle technique,
a 25-G Whitacre needle (Changshen Co.) was inserted into the subarachnoid space.
After cerebrospinal fluid was obtained, hyperbaric 0.75% bupivacaine 12 mg was
injected within 40 seconds without barbotage. The spinal needle was removed and an
epidural catheter was inserted 3 to 4 cm into the epidural space. The upper anesthesia
level was determined by measuring the temperature sensation to an alcohol swab
midline every minute for 10 minutes after the subarachnoid injection; the upper an-
esthesia level was controlled at about the 6th thoracic dermatome.
The IV infusion was maintained using Ringer's solution at a rate of 10 mUmin via
an infusion pump. All hysterectomies were successfully completed with CSEA by 1 of
2 appointed teams of gynecologists.
PCEA AND ANALGESIC EFFICACY
Ten minutes before the end of the surgery, epidural morphine 1 mg and ropivacaine
6 mg diluted with isotonic saline to 5 mL, as a loading dose, and IV ondansetron
8 mg were administered. After the surgery, patients received PCEA (the same pre-
scription) via an electronic pump (AMI Incorporation, Kawasaki, Japan). The pre-
scription for the PCEA was as follows: morphine 4 mg, ropivacaine 120 mg, and
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ondansetron 24 mg diluted with saline to 100 mL; background infusion 1 mL/h;
bolus 1 mL; and lockout time 10 minutes.
The patients evaluated analgesic efficacy using a visual analog scale (VAS) and the
Bruggemann Comfort Scale (BCS) at 4, 24, and 48 hours after surgery. On the VAS,
patients evaluated their pain using scores from 0 to 10 (0 = no pain and 10 = most
severe pain). On the BCS, patients evaluated their pain using scores from 0 to 4 (0 =
continuous pain; 1 = no pain without movement, but serious pain when breathing
deeply or coughing; 2 = no pain without movement, but mild pain when breathing
deeply or coughing; 3 = no pain, even when breathing deeply; and 4 = no pain when
coughing).
A blinded evaluator (Y-H.Q.) recorded the epidural morphine consumption dur-
ing the first 24 and 48 hours after surgery and the total morphine consumption dur-
ing 48 hours after surgery for all patients.
DETERMINATION OF CHEMOKINE CONCENTRATIONS
Venous blood from a noninfused median cubital vein in the supine position were
drawn in ethylenediaminetetraacetic acid-containing tubes at 4 time points: before
(baseline) and immediately after (0 hour) the induction of anesthesia, and 24 and
48 hours after surgery to determine plasma concentrations of MCP-1 and SDF-1a
via enzyme-linked immunosorbent assay (ELISA) (Biosource Co., Camarillo, Cali-
fornia). ELISA was performed according to the manufacturer's instructions, and all
samples were analyzed at a dilution resulting in concentrations within the range of
the standard curve. The minimum detectable concentrations ofMCP-1 and SDF-1a
were 1 and 10 pg/mL, respectively.
STATISTICAL ANALYSIS
Data are expressed as mean (SD) or median (range). Statistical analysis was per-
formed using SAS software version 9.1 for Windows (SAS Institute, Inc., Cary,
North Carolina). Age, weight, duration of surgery, and morphine consumption were
compared using 1-way analysis of variance. Plasma concentrations of chemokines
were compared using a general linear model for 2-way repeated measures analysis
of variance followed by contrast tests for multiple comparisons between the 3 groups.
Nonparametric data (ie, ASA physical status, VAS score, and BCS score) were com-




Fifty patients were solicited to enroll in the study, but 5 were excluded. Forty-
five patients (mean [SD} age, 41 [5} years; mean [SD} weight, 54 [6} kg) were
enrolled in the study and were randomized into 3 groups (n = 15 each). All
45 patients completed the study. There were no significant differences between
the 3 groups with regard to age, weight, ASA physical status, or duration of sur-
gery (Table I).
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Table I. Demographic and clinical characteristics in the study of patients undergoing
hysterectomy (n = 15 patients per group).*
Characteristic Group it Group 21'
Age, mean (SO), y 41 (5) 42 (6)
Weight, mean (SO), kg 56 (5) 53 (6)
ASA physical status (range) I (I-II) I (I-II)






ASA = American Society of Anesthesiologists.
*There were no significant between-group differences.
t Patients received lornoxicam 8 mg.
l' Patients received lornoxicam 16 mg.
ANALGESIC EFFICACY AND MORPHINE CONSUMPTION
No significant between-group differences were found in the VAS or BCS scores
(Table II).
No significant between-group differences were found in morphine consumption
(Table III).
CHEMOKINE CONCENTRATIONS
No significant between-group differences were found in baseline concentrations of
MCP-I or SDF-Ia (Table IV).
Table II. Visual analog scale (VAS)* and Bruggemann Comfort Scale (BCS)t scores at 4,
24, and 48 hours after surgery in the study patients undergoing hysterectomy
(n = 15 patients per group).'" Data are median (range).
Group Scale 4 Hours 24 Hours 48 Hours
1§ VAS 1 (1-2) 2 (1-3) 1 (1-3)
BCS 4 (3-4) 3 (2-4) 3 (2-4)
211 VAS 1 (1-2) 1 (1-3) 1 (1-3)
BCS 4 (3-4) 4 (3-4) 3 (3-4)
Control VAS 1 (1-2) 2 (1-4) 1 (1-4)
BCS 3 (3-4) 3 (2-4) 3 (2-4)
*VAS scores: 0 = no pain to 10 = most severe pain.
t BCS scores: 0 = continuous pain; 1 = no pain without movement, but serious pain when breathing
deeply or coughing; 2 = no pain without movement, but mild pain when breathing deeply or coughing;
3 = no pain, even when breathing deeply; and 4 = no pain when coughing.
l' There were no significant between-group differences.
§ Patients received lornoxicam 8 mg.
II Patients received lornoxicam 16 mg.
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Table III. Morphine consumption in the 48 hours after surgery (n = 15 patients per
group).* Data are mean (SO) mg.
Morphine Consumption
First 24 Hours Second 24 Hours
Group Postsurgery Postsurgery Total
I t 2.0 (0.4) 1.5 (0.3) 3.5 (0.3)
21' 2.0 (0.3) 1.4 (0.4) 3.4 (0.4)
Control 2.2 (0.4) 1.4 (0.3) 3.6 (0.4)
*There were no significant between-group differences.
t Patients received lornoxicam 8 mg.
l' Patients received lornoxicam 16 mg.
Compared with baseline values, MCP-l and SDF-la concentrations increased sig-
nificantly in all 3 groups immediately after surgery (all, P < 0.0l). Immediately after
surgery, MCP-l and SDF-la concentrations were significantly lower in groups land
2 than in the control group (both, P < 0.0l); the difference between groups land 2
was not significant (Table IV).
Twenty-four hours after surgery, MCP-l and SDF-la concentrations in the control
group had not returned to near-baseline values (both, P < 0.0l), but MCP-l and SDF-
la concentrations in groups land 2 returned to near-baseline values and were signifi-
cantly lower than those in the control group (both, P < 0.05) (Table IV).
At 48 hours after surgery, MCP-l and SDF-la concentrations had returned to near-
baseline values in the control group and no significant between-group differences were
found (Table IV).
Table IV. Plasma concentrations of monocyte chemotactic protein-1 (MCP-1) and stro-
mal cell-derived factor-1a (50F-1a) (n = 15 patients per group). Data are mean
(SO) pgjmL.
Before o Hours 24 Hours 48 Hours
Group Chemokine Anesthesia Postsurgery Postsurgery Postsurgery
1* MCP-l 29 (8) 46 (l1)tT 30 (9)§ 31 (8)
SDF-la 901 (68) 1012 (97)tT 889 (80)§ 883 (75)
211 MCP-l 31 (9) 47 (l1)tT 32 (8)§ 33 (8)
SDF-la 883 (96) 986 (82)n 879 (72)§ 864 (85)
Control MCP-l 31 (7) 76 (20)t 44 (9)t 32 (7)
SDF-la 862 (79) 1885 (150)t 1016 (83)t 842 (98)
*Patients received lornoxicam 8 mg.
t p < 0.01 versus baseline.
l' P < 0.01 versus control.
§ P < 0.05 versus control.
II Patients received lornoxicam 16 mg.
~ P < 0.05 versus baseline.
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DISCUSSION
This study found that preemptive IV lornoxicam treatment was associated with at-
tenuation of increases in MCP-l and SDF-la concentrations in these women undergo-
ing hysterectomy who were treated with CSEA and PCEA (primary end point). How-
ever, preemptive IV lornoxicam treatment was not associated with improved analgesic
efficacy of morphine or reduced consumption of morphine in these patients.
Chemokines, a group of cytokines with chemotactic and activating effects on neu-
trophils, eosinophils, monocytes, and/or lymphocytes, have been identified as impor-
tant mediators in both acute and chronic human inflammatory disorders. 9,lo Chemo-
kines appear to act in at least 2 ways: through direct chemoattraction and by activating
leukocyte integrins to bind to their adhesion receptors on endothelial cells.9 Surgery
is associated with a systemic inflammatory response, and many inflammatory cyto-
kines increase after surgery.1O,l2,l3 In this study, MCP-l and SDF-la concentrations
increased in women immediately after hysterectomy, which implied that hysterecto-
my might induce significant proinflammatory responses. 9- l3 Preemptive IV lornoxi-
cam treatment was found to attenuate the increase in MCP-l and SDF-la concentra-
tions, which suggested that the treatment might alleviate hysterectomy-induced
proinflammatory responses and thus be beneficial to these patients.9- l3 Risnes et allo
reported that MCP-l concentration was associated with a significant increase after
open heart surgery.
Stephens et al6 concluded that NSAIDs had an important role in extending the use
of balanced, multimodal analgesia to a broad surgical population, thus improving
patient outcomes after surgery. Studies found that lornoxicam and opioids might have
a synergistic effect.s,6 However, in the present study, lornoxicam was not associated
with a decrease in morphine use, perhaps because the loading dose and the back-
ground infusion rate were too large, which might have obscured the difference in
morphine use between the 3 groups. We assumed that the differences in immune ef-
fects between the lornoxicam groups and the control group were due to the pharma-
codynamics of lornoxicam rather than morphine.
Lornoxicam has been found to inhibit inflammatory responses and relieve pain. s- 7 ,l4
We reported in a previous studys that perioperative IV lornoxicam 16-mg treatment
might ameliorate the reductions in the levels of CD3+, CD3+CD4+, CD3-CD16+
CD56+, and CD3+CD25+ during patient-controlled IV analgesia with tramadol and
reduce the consumption of IV tramadol. Based on the findings of the present study,
IV lornoxicam treatment might be helpful in ameliorating immune function during
PCEA with morphine, although it did not reduce epidural morphine consumption.
However, the underlying mechanisms by which lornoxicam reduces the expression of
MCP-l and SDF-la are unclear. 6,l4 Further studies are needed to explore the possible
mechanisms and clinical utility of lornoxicam.
Morphine is often associated with adverse events, including urinary retention, nau-
sea and vomiting, drowsiness, apnea, and pruritus. ls In the present study, urethral
catheterization was performed to facilitate hysterectomy, a large dose of ondansetron
was administered to prevent vomiting, and total morphine consumption was small in
all patients. Consequently, we did not record the adverse events during PCEA. How-
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ever, some patients complained of adverse events, especially pruritus. Not recording
adverse events during PCEA was a limitation of this study. The small sample size and
the fact that all the study participants were women were also limitations. Also, out-
comes data were not collected.
CONCLUSIONS
Preemptive treatment with IV lornoxicam 8 and 16 mg was not associated with im-
proved analgesic efficacy of epidural morphine or with reduced morphine consump-
tion. However, it was associated with attenuated MCP-1 and SDF-1a concentrations
immediately and 24 hours after hysterectomy and was associated with more rapid
resolution to near-baseline concentrations of both cytokines in these patients com-
pared with controls. There was no significant difference between the 2 lornoxicam
doses in the expression of the chemokines.
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